Roadshow
PANCREASaver
PANCREASaver
A Novel Computer-Assisted Detection (CAD) Tool for Early Pancreatic Cancer (PC)
Computed tomography (CT) is the major modality for detecting PC, but small PCs are often obscure with approximately 40% of tumors less than 2 cm being missed on CT.
PANCREASaver is an automatic tool which determines whether CT images harbor PC and indicate tumor location without requiring manual image processing.
｜FDA Breakthrough Device
｜Taiwan FDA Approved
｜US and Taiwan Patented
｜Validated by Nationwide Real-World Data
- Radiology 306(1):172-182, 2023.
- 2023 RSNA Margulis Award
Join us at BIO 2025, June 16-19 in Boston, where PanCAD.ai Co., Ltd. will be showcasing our cutting-edge solutions and services. We can't wait to connect with you to discuss how we're shaping the future of biotechnology. Find us at Booth 1645. See you there!
#BIO2025#TAIWAN PAVILION
PANCREASaver, that can improve the detection of early PC on contrast-enhanced CT to address the pressing unmet need. PANCREASaver has been approved by the Taiwan FDA and designated as a Breakthrough Device by the US FDA.
- Established 2022
- Company PanCAD.ai Co., Ltd.
- Telephone +886-2-2331-3971
- Email info@pancad.ai
- Address 2F.-1, No. 72, Sec. 1, Zhongxiao W. Rd., Zhongzheng Dist., Taipei City 100007, Taiwan (R.O.C.)
Detecting pancreatic cancer (PC) while the tumor is smaller than 2 cm represents the only chance of cure. Still, approximately 40% of PCs smaller than 2 cm are missed on the primary detection modality of computed tomography (CT). PanCAD.ai, a spinoff of National Taiwan University and National Taiwan University Hospital, has developed a novel AI CADe/x tool, PANCREASaver, that can improve the detection of early PC on contrast-enhanced CT to address the pressing unmet need. PANCREASaver has been approved by the Taiwan FDA and designated as a Breakthrough Device by the US FDA.